Investigation of Cancer Stem Cell Surface Markers In The Tumor Tissues of Patients Who Had Liver Transplantation Due To Hepatocellular Cancer And Evaluation of The Effect of These Markers on Prognosis

Year 2024, Volume: 8 Issue: 3, 704 - 709, 30.09.2024

Tufan Egeli , Tarkan Unek , Anıl Aysal Ağalar , İlkay Tuğba Ünek , Cihan Agalar , Mücahit Özbilgin , Özgül Sağol , Ali Durubey Çevlik , Aylin Bacakoğlu , Mesut Akarsu , Nur Olgun , Yasemin Başbınar , İbrahim Astarcioğlu , Hülya Ellidokuz

https://doi.org/10.30621/jbachs.1521349

https://izlik.org/JA93HU92GW

Abstract

Purpose: To investigate the relevance between cancer stem cell(CSC) markers and tumor progression in hepatocellular carcinoma(HCC).
Methods: Data of patients who underwent liver transplantation(LT) for HCC between February 1998 and September 2018 were collected. Patients over 18 years of age were included. Immunohistochemical staining were performed in paraffin blocks of liver explants containing HCC in terms of CSC markers, CD13, CD44, CD47, CD90 and EpCAM. Follow-up period, cancer recurrence, disease-free and overall survival were investigated.
Results: There were 71 patients who met the inclusion criteria. Optimal evaluation conditions were not met for CD13 and CD90 staining. Disease recurrence was found to be more frequent in CD 44+ cases (p=0.008). Disease-free survival was significantly longer in CD44- group(160.2 vs 103.0 months, p=0.043). Overall survival was significantly shorter in CD44+ cases(171.7 vs 107.8 months, p=0.018). No statistically difference was found between CD47+/- or EpCAM+/- groups in terms of recurrence (p=0.27, p=0.24). There was no significant difference in disease-free and overall survival in CD47+/- or EpCAM+/- cases, respectively (CD47+/-; p=0.82, p=0.90, EpCAM; p=0.76, p=0.69).
Conclusion: Positive CD44markers in HCC is associated with a more aggressive course of disease. Targeted therapies for CD44antigens of CSCs may prevent disease recurrence and increase survival.

Keywords

Hepatocellular Cancer , cancer stem cell , tumor markers , liver transplantation

References

• Rozeik MS, Hammam OA, Ali AI, et al. Evaluation of CD44 and CD133 as markers of liver cancer stem cells in Egyptian patients with HCV-induced chronic liver diseases versus hepatocellular carcinoma. Electron Physician 2017;25(7):4708-17.
• Orcutt ST, Anaya DA. Liver Resection and Surgical Strategies forManagement of Primary Liver Cancer. Cancer Control 2018;25(1):1073274817744621
• Lin HC, Yang YS, Teng CJ, et al. Liver resection for hepatocellular carcinoma in patients with hematological malignancies. World J Surg Oncol 2017;15(1):194.
• de'Angelis N, Landi F, Carra MC, Azoulay D. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World J Gastroenterol 2015;21(39):11185-98.
• Kakodkar R, Soin AS. Liver Transplantation for HCC: A Review. Indian J Surg 2011;74(1):100-17.
• Woerns MA, Galle PR: Future perspectives in hepatocellular carcinoma. Digest Liver Dis 2010;42 (Suppl 3): 302-9.
• Rountree CB, Mishra L, Willenbring H. Stem cells in liver diseases and cancer: Recent advances on the path to new therapies. Hepatology 2012;55: 298-306.
• Qiu L, Li H, Fu S, Chen X, Lu L. Surface markers of liver cancer stem cells and innovative targeted-therapy strategies for HCC. Oncol Lett 2018;15(2):2039-48.
• Wang K, Sun D. Cancer stem cells of hepatocellular carcinoma. Oncotarget 2018;(9): 23306-314.
• Chiba T, Iwama A, Yokosuka O. Cancer stem cells in hepatocellular carcinoma: Therapeutic implications based on stem cell biology. Hepatol Res 2016;46(1):50-7.
• Fan ST, Mau Lo C, Poon RT, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: A 20-year experience. Ann Surg 2011;253: 745-58.
• Bruix J, Sherman M; American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: An update. Hepatology 2011;53: 1020-22.
• Xia P, Liu DH. Cancer stem cell markers for liver cancer and pancreatic cancer. Stem Cell Research 2022;60(10271).
• Egeli T, Unek T, Agalar C, et al. Analysis of Causes and Risk Factors for Late Mortality After Liver Transplant: How Can We Obtain Better Long-Term Survival? Exp Clin Transplant 2020;18(2):182-187.
• Egeli T, Unek T, Agalar C, et al. Survival Outcomes After Liver Transplantation in Elderly Patients: A Single-Center Retrospective Analysis. Transplant Proc 2019;51(4):1143-1146.
• Agalar C, Egeli T, Unek T, et al. The Predictive Ability of the Glasgow Prognostic Score and Variants in Both Deceased Donor and Living Donor Liver Transplantation for Hepatocellular Cancer. Transplant Proc 2019;51(4):1134-1138.
• Egeli T, Unek T, Ozbilgin M, et al. De Novo Malignancies After Liver Transplantation: A Single Institution Experience. Exp Clin Transplant 2019;17(1):74-78.
• Pehlivanoglu B, Aysal A, Agalar C, et al. Peritumoral histopathologic findings in patients with chronic viral hepatitis-associated hepatocellular carcinoma. APMIS 2022;130(6):346-356.
• Xiao Y, Lin M, Jiang X, et al. The Recent Advances on Liver Cancer Stem Cells: Biomarkers, Separation, and Therapy. Anal Cell Pathol (Amst) 2017;2017:5108653.
• Sun JH, Luo Q, Liu LL, Song GB. Liver cancer stem cell markers: Progression and therapeutic implications. World J Gastroenterol 2016;22(13):3547-57.